-
公开(公告)号：US12024547B2
公开(公告)日：2024-07-02
申请号：US17707857
申请日：2022-03-29
CPC分类号： C07K14/81 , A61K38/55 , A61K38/57 , C07K14/811 , C07K14/8135 , A61K38/00 , C07K2319/30
摘要： SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US11981943B2
公开(公告)日：2024-05-14
申请号：US16340657
申请日：2017-10-02
发明人： Vinit B. Mahajan , Alexander G. Bassuk , Diana F. Colgan , Gabriel Velez , Kellie Schaefer , Marcus Toral , Shu Wu , Lokesh Gakhar
IPC分类号： C12N9/64 , A61K9/08 , A61K38/00 , A61P27/02 , A61P29/00 , C07K14/49 , C07K14/81 , G01N33/573 , C07K7/64
CPC分类号： C12N9/6472 , A61K9/08 , A61P27/02 , A61P29/00 , C07K14/49 , C07K14/81 , C07K14/8139 , C12Y304/22 , G01N33/573 , A61K38/00 , C07K7/64 , C07K2319/00
摘要： The present disclosure provides CAPN5 substrates and CAPN5 inhibitors, nucleic acids encoding CAPN5 substrates or CAPN5 inhibitors, methods to deliver CAPN5 substrate or CAPN5 inhibitor agents to the eye, and methods of identifying inhibitors of CAPN5.
-
公开(公告)号：US11845786B2
公开(公告)日：2023-12-19
申请号：US17533038
申请日：2021-11-22
发明人： Daisuke Nishimiya , Masakazu Tamura
CPC分类号： C07K14/81 , A61K47/62 , A61K47/68 , C07K14/001 , A61K38/00
摘要： A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
-
公开(公告)号：US20230234995A1
公开(公告)日：2023-07-27
申请号：US17781873
申请日：2020-12-01
申请人： LG CHEM, LTD
发明人： Byeong Eun MIN , Yeonchul KIM , Young Sam PARK , Saem JUNG
IPC分类号： C07K14/47 , C12N15/90 , C12N5/00 , C12N9/64 , C12N9/02 , C12N9/20 , C12N9/90 , C07K14/52 , C07K14/81 , C07K14/78 , C07K14/435
CPC分类号： C07K14/47 , C07K14/78 , C07K14/81 , C07K14/523 , C07K14/43595 , C12N5/00 , C12N9/20 , C12N9/0051 , C12N9/90 , C12N9/6472 , C12N15/907 , C12Y108/03002 , C12Y301/01034 , C12Y304/22001 , C12Y503/04001
摘要： The present invention relates to a CHO cell-derived protein secretory factor, an expression cassette in which a nucleic acid sequence encoding the protein secretory factor; and a gene encoding a target protein are operably linked, an expression vector comprising the expression cassette, a transformed cell into which the expression vector is introduced, and a method for producing a target protein using the transformed cell.
-
公开(公告)号：US20170282095A1
公开(公告)日：2017-10-05
申请号：US15451743
申请日：2017-03-07
发明人： Allan Otto Fog Lihme
CPC分类号： B01D15/08 , B01D15/206 , B01D15/424 , C07K1/16 , C07K14/47 , C07K14/75 , C07K14/755 , C07K14/76 , C07K14/79 , C07K14/81 , C07K16/00
摘要： The present invention provides a process for the isolation of one or more proteins) from a protein solution. The process comprising the steps of: a) providing a protein solution comprising one or more specific proteins) and having a preset pH and a preset ionic strength or conductivity, b) applying the protein solution to a packed bed or expanded bed column comprising an adsorbent, and c) obtaining one or more proteins) from the column; wherein the protein solution has been supplemented with an alcohol.
-
公开(公告)号：US20160376305A1
公开(公告)日：2016-12-29
申请号：US15214706
申请日：2016-07-20
申请人： TissueTech, Inc.
发明人： Scheffer TSENG , Hua HE , Sean TIGHE , Suzhen ZHANG , Ying-Tieng ZHU
CPC分类号： C07K1/36 , A61K38/00 , A61K38/191 , A61K47/55 , A61K47/69 , A61K47/6957 , A61L27/34 , A61L27/54 , A61L29/085 , A61L29/16 , A61L31/10 , A61L31/16 , A61L2300/236 , A61L2300/252 , A61L2300/41 , A61L2300/412 , A61L2300/426 , C07K14/47 , C07K14/525 , C07K14/81 , C07K19/00
摘要： Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.
-
7.发明授权Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses 有权用作诱导抗原特异性T细胞应答的免疫原性增强子的融合蛋白公开(公告)号：US09481714B2
公开(公告)日：2016-11-01
申请号：US14095760
申请日：2013-12-03
发明人： Chia-Mao Wu , Hsiu-Kang Chang
IPC分类号： A61K39/00 , C07K14/005 , A61K39/21 , A61K47/48 , A61K39/385 , C07K14/705 , A61K39/12 , A61K39/135 , A61K39/17 , C07K14/81 , C12N9/10 , C12N9/14 , C07K14/21
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
摘要翻译： 公开了用作增强抗原特异性T细胞应答的免疫原增强剂的融合蛋白。 融合蛋白包括：（a）抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）蛋白转导结构域; 和（c）病原体的抗原，其中APC结合结构域或CD91受体结合结构域位于融合蛋白的N末端，并且病原体的抗原位于 蛋白转导结构域。 蛋白转导结构域选自：（i）包含T细胞致敏信号转导肽，接头和易位肽的融合多肽; （ii）T细胞增感信号转导肽; 和（iii）长度为34-112个氨基酸残基的易位肽。
-
8.发明授权Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome 有权使用α-1-抗胰蛋白酶制备用于治疗慢性疲劳综合征的药物公开(公告)号：US09205134B2
公开(公告)日：2015-12-08
申请号：US12822764
申请日：2010-06-24
CPC分类号： A61K38/4826 , A61K38/56 , A61K38/57 , C07K14/81
摘要： The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.
摘要翻译： 本发明涉及α-1-抗胰蛋白酶用于制备用于治疗慢性疲劳综合征的有效药物的用途。 此外，本发明涉及使用足够的α-1-抗胰蛋白酶含量的血浆或其它治疗形式，以每kg体重获得每kg体重6mg或更多的α-1-抗胰蛋白酶的剂量， 1天和31天。
-
公开(公告)号：US20140050727A1
公开(公告)日：2014-02-20
申请号：US13972778
申请日：2013-08-21
发明人： Shoji FURUSAKO , Kazuyuki NAKAYAMA , Yoshitaka HOSAKA , Tetsushi KAWAHARA , Masaki NAKAMURA , Takashi TAKEUCHI
CPC分类号： C07K16/2896 , A61K38/00 , A61K39/39541 , A61K2039/505 , C07K14/81 , C07K2317/24 , C07K2319/00 , A61K2300/00
摘要： A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
摘要翻译： 提供了包含（I）抗CD14抗体或其活性片段或其衍生物和（II）蛋白酶抑制剂或其活性片段或其衍生物的蛋白质。
-
10.发明授权Protease inhibitor: protease sensitivity expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria 有权蛋白酶抑制剂：蛋白酶敏感性表达系统和提高细菌递送的蛋白质和噬菌体和噬菌体的治疗活性和特异性的方法公开(公告)号：US08623350B1
公开(公告)日：2014-01-07
申请号：US13562488
申请日：2012-07-31
CPC分类号： C07K14/81 , A61K35/74 , A61K38/00 , A61K38/164 , A61K38/55 , C07K14/005 , C07K14/245 , C07K2319/50 , C07K2319/55 , C12N9/0071 , C12N9/22 , C12N15/1135 , C12N15/1137 , C12N15/74 , C12N2310/14 , C12N2310/141 , Y02A50/483
摘要： The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents that results in their localized production within the target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. Inactivation is also accomplished by engineering protease degradation sites within the therapeutic construct for proteases, preferably those that are under-expressed within the target tissue yet present in non-target tissues within the body, resulting in therapeutic activity within the target tissue and inactivation outside of the target tissue. Novel chimeric proteins secreted by bacteria are also described. The chimeric proteins include chimeric toxins targeted to neoplastic cells and cells of the immune system. Novel combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described. Non-conjugative bacteria capable of delivering phage/phagemids expression cassettes for DNA and RNA-based therapeutics are also described.
摘要翻译： 本发明使用蛋白酶抑制剂和蛋白酶敏感性治疗剂的共表达，其导致其在靶组织内的局部生产和靶组织外的失活，从而增加治疗活性并降低全身毒性。 失活还可以通过在蛋白酶治疗构建体内工程化蛋白酶降解位点来实现，优选在目标组织内尚未存在于靶组织内的非靶组织中的蛋白酶降解位点，导致靶组织内的治疗活性， 目标组织。 还描述了细菌分泌的新型嵌合蛋白。 嵌合蛋白包括靶向肿瘤细胞的嵌合毒素和免疫系统的细胞。 还描述了这些蛋白酶抑制剂的新型组合疗法：表达嵌合毒素的细菌以及小分子和生物制剂。 还描述了能够递送用于DNA和RNA的治疗剂的噬菌体/噬菌粒表达盒的非共轭细菌。
-
-
-
-
-
-
-
-
-
搜索结果
205 条记录 (耗时 0.037 秒)
